Copyright
©The Author(s) 2022.
World J Hepatol. Aug 27, 2022; 14(8): 1550-1561
Published online Aug 27, 2022. doi: 10.4254/wjh.v14.i8.1550
Published online Aug 27, 2022. doi: 10.4254/wjh.v14.i8.1550
No | Ref. | Definition of HP | PHH, n (%) | NP, n (%) | Type of liver resection (%) | Histopathology (%) | Post-operative phosphate replacement regime | Phosphate replacement, n (%) |
1 | Buell et al[14], 1998 | < 2.5 mg/dL | 21/35 (60) | 14/35 (40) | Major hepatectomy (NR); Cryosurgery (NR) | CRLM: 8 (23) HCC: 4 (11) Others: 23 (66) | For phosphate < 3.0 mg/dL: sodium phosphate or potassium phosphate HP: mean of | NR |
2 | George et al[11], 1992 | NR | 44/44 (100) | 0 | Right hepatectomy and extended right hepatectomy | NR | NR | NR |
3 | Giovannini et al[12], 2002 | Normal: > 2.5 mg/dL; Mild-moderate: 1.6-2.5 mg/dL; Severe: < 1.5 mg/dL | 38/59 (64.4) | 21/59 (35.6) | Major hepatectomy (58); Minor hepatectomy (42) | CRLM: 10 (17) ICC: 7 (12) HCC: 16 (27) GBC: 2 (3) Others: 24 (41) | If > POD3 and oral feeding cannot be resumed: parenteral phosphate (fructose 1-6 diphosphate or potassium phosphate) at 20-50 mmol/d | NR |
4 | Hallet et al[10], 2016 | ≤ 0.65 mmol/L | 223/402 (55.5) | 179/402 (44.5) | Major hepatectomy (52) Minor (48) Hepatectomy | CRLM: 260 (65) ICC: 53 (13) HCC: 27 (7)Others: 62 (15) | Based on serum phosphate: Intravenous potassium phosphate or sodium phosphate | NR |
5 | Serrano et al[38], 2019 | Normal: > 2.5 mg/dL; Mild: 1.6-2.5 mg/dL; Moderate: 1.0-1.5 mg/dL; Severe: < 1.0 mg/dL | 161 | Living donor hepatectomy | NA | Elemental phosphate based on phosphate levels: < 1.1 mg/dL: 25 mmol 1.1-1.9 mg/dL: 20 mmol 2.0-2.3 mg/dL: 15 mmol 2.4-2.7 mg/ dL: 10 mmol | NR | |
6 | Squires et al[13], 2014 | Normal: > 2.5 mg/dL; Mild: 1.6-2.5 mg/dL; Moderate: 1.0-1.5 mg/dL; Severe: < 1.0 mg/dL | 488/719 (67.9) | 231/719 (32.1) | Extended left hepatectomy (6) Extended right hepatectomy (20) Left hemihepatectomy (23) Right hemihepatectomy (39) Central hepatectomy (2) Non-anatomical (10) | CRML: 229 (32) HCC: 69 (9) ICC: 88 (12) Metastatic NET: 34 (5) Other: 299 (42) | Discretion of surgeon Median replacement: 55 mmol (range 10-170 mmol) | 469 (69) |
7 | Tan et al[39], 2003 | Normal: > 2.5 mg/dL; Moderate: 1.5-2.5 mg/dL; Severe: 1.0-1.5 mg/dL; Profound: < 1.0 mg/dL | 89/95 (93.7) | 6/95 (6.3) | Right-lobe living donor hepatectomy: Right hepatectomy (94); Left lateral segmentectomy (5); Left lobectomy (11) | NA | Based on phosphate deficit: intravenous or oral phosphate | NR |
8 | Yuan et al[40], 2010 | Normal: > 2.5 mg/dL; Mild: 1.5-2.5 mg/dL; Moderate: 1.0-1.5 mg/dL; Severe: < 1.0 mg/dL | Overall: 100/102 (98) Mild: 56/102 Moderate: 25/102 Severe: 19/102 | 2/102 (2) | Living donor hemi-hepatectomy | NA | Severe HP: Intravenous phosphate | 7/19 (36.8) |
Mean nadir phosphate, mg/dLa | Mean INRa | Length of stay, d | Post-hepatectomy liver failure | Any morbidity | 30 d mortality | ||||||||||||||
No | Ref. | PHH | NP | P value | PHH | NP | P value | PHH | NP | P value | PHH | NP | P value | PHH | NP | P value | PHH | NP | P value |
1 | Buell et al[14], 1998 | 2.1 ± 0.1b | 3.0 ± 0.2b | < 0.05 | NR | 16.22 ± 12.09 | 11.22 ± 7.03 | NR | NR | 17/21 (81) | 4/14 (29) | < 0.05 | 1/21 (5) | 0/14 (0) | NR | ||||
2 | George et al[11], 1992 | NR | NR | NR | 1/44 (2) | 0/0 | NA | 11/44 (25) | 0/0 (0) | NA | NR | ||||||||
3 | Giovannini et al[12], 2002 | 1.7 ± 0.8 (POD3) | NR | NR | NR | NR | Mild-moderate: 4/23 (17) Severe: 9/15 (60) | 3/21 (14) | < 0.001c | Mild-moderate: 1/23 (4) Severe: 3/12 (20) | 1/21 (5) | NR | |||||||
4 | Hallet et al[10], 2016 | 1.52 ± 0.31d | 2.72 ± 0.74d | < 0.01 | 1.51 ± 0.37 | 1.53 ± 0.91 | 0.83 | 7 (6-10) | 7 (5-11) | 0.55 | 44/223 (19.7) | 20/179 (11.2) | 0.02 | Major morbidity: 13/223 (5.8) | Major morbidity: 12/179 (6.7) | 0.56 | 9/223 (4.0) | 4/179 (2.2) | 0.31 |
5 | Serrano et al[38], 2019 | 2.00e (recorded at median 1.6 d post-operatively) | NR | 7.2 ± 3.4e | NR | 10/161 (6.2) | NR | Any morbidity > 30 d: 19/161 (11.8) | NR | NR | |||||||||
6 | Squires et al[13], 2014 | 2.2 [1.7-2.8] | NR | NR | Moderate: 8.0% Severe: 8.5% Profound: 3.4%f | 12.3%f | 0.008 | Major morbidity: Moderate: 20.1% Severe: 19.5% Profound: 16.7%f | 30.3%f | 0.037 | Moderate: 3.8% Severe: 2.8% Profound: 0% | 6.5% | 0.010 | ||||||
7 | Tan et al[39], 2003 | 2.6 (range 1.3-5.0) | NR | NR | NR | NR | Any morbidity: 8/95 (8.4) | NR | NR | ||||||||||
8 | Yuan et al[40], 2010 | 1.89 ± 0.72 (POD3) | NR | Mild: 1.51 ± 0.26 Moderate: 1.43 ± 0.19 Severe: 1.95 ± 0.40 | NR | < 0.001g | NR | 14/100 (14) | 0/2 (0) | NR | NR | NR |
Indications | Formulation | Route of administration | Composition | Recommended dosage | Special considerations | |
Mild hypophosphatemia (0.65-0.81 mmol/L) | Phospho-soda (C.B. Fleet Company, Virginia) | Oral | 180mg Na2HPO4 · 7H2O + 480 mg NaH2PO4 · H2O/mL Phosphate: 4.150 mmol/mL Sodium: 4.822 mEq/mL Potassium: 0 | 1000mg/d | Chronic renal failure / reduced glomerular filtration rate: to use half of recommended initial dose Causes diarrhoea | |
Phospha 250 Neutral (Rising Pharmaceuticals, Inc., United States) | Oral | Elemental phosphorus 250 mg (8 mmol), Sodium 298 mg (13 mEq), and Potassium 45 mg (1.1 mEq) | ||||
Moderate hypophosphatemia (0.32-0.65 mmol/L) | Not on ventilator | Phospho-soda (C.B. Fleet Company, Virginia) | (same as above) | (same as above) | If ≥1.5 mg/dL: 1 mmol/kg of elemental phosphorus (minimum of 40 mmol and a maximum of 80 mmol) in 3-4 doses over 24 h If < 1.5 mg/dL: 1.3 mmol/kg of elemental phosphorus (maximum of 100 mmol) in 3-4 doses over 24 h | (same as above) |
On ventilator | Sodium phosphate (Abbott Laboratories, North Chicago, Illinois) | Intravenous | 142 mg Na2HPO4 + 276 mg NaH2PO4 · H2O/mL Phosphate: 3.0 mmol/mL Sodium: 4.0 mEq/mL | 0.08 mg/kg over 2-6 h if recent and uncomplicated HP 0.16 mg/kg over 2-6 h if prolonged and has multiple causes Maximum of 20 mmol/h | Chronic renal failure / reduced glomerular filtration rate: to use half of recommended initial dose | |
Potassium phosphate (Invenex Pharmaceuticals, Grand Island, New York) | 236 mg K2HPO4 + 224 mg KH2PO4/mL Phosphate: 3.003 mmol/mL 4.360 mEq/mL | Chronic renal failure / reduced glomerular filtration rate: to use half of recommended initial dose To avoid if potassium > 4mmol/L | ||||
Severe hypophosphatemia (< 0.32 mmol/L) / Critically ill patients, or with severe complications of hypophosphatemia | Sodium phosphate or potassium phospahte | (same as above) | (same as above) | 0.08-0.16 mg/kg over 2-6 h | (same as above) |
- Citation: Chan KS, Mohan S, Shelat VG. Outcomes of patients with post-hepatectomy hypophosphatemia: A narrative review. World J Hepatol 2022; 14(8): 1550-1561
- URL: https://www.wjgnet.com/1948-5182/full/v14/i8/1550.htm
- DOI: https://dx.doi.org/10.4254/wjh.v14.i8.1550